2010
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Abstract: Background Disease-modifying therapies for Alzheimer’s disease (AD) would be most beneficial if applied during the ‘preclinical’ stage (pathology present with cognition intact) before significant neuronal loss occurs. Therefore, biomarkers that can detect AD pathology in its early stages and predict dementia onset and progression will be invaluable for patient care and efficient clinical trial design. Methods 2D–difference gel electrophoresis and liquid chromatography tandem mass spectrometry were used to me…
Search citation statements
Paper Sections
Select...
331
125
99
15
Citation Types
45
512
9
1
Year Published
2011
2026
Publication Types
Select...
423
44
26
26
Relationship
27
492
Authors
Journals
Cited by 494 publications
(567 citation statements)
References 50 publications
45
512
9
1
“…In contrast to previous studies of the CSF in aging 72,85 and AD, 76,77,79,82,86 our analyses reveal that the same biological processes change in both of these conditions but to a different extent. This suggests that CSF changes in AD reflect a perturbed process of physiological aging.…”
Section: Discussion and Study Conclusioncontrasting
confidence: 99%
“…In contrast to previous studies of the CSF in aging 72,85 and AD, 76,77,79,82,86 our analyses reveal that the same biological processes change in both of these conditions but to a different extent. This suggests that CSF changes in AD reflect a perturbed process of physiological aging.…”
Section: Discussion and Study Conclusioncontrasting
confidence: 99%
“…Our finding of increased CSF YKL-40 levels in APOE ε4 carriers contrasts with previous literature [18] , [19] , [20] , including one article published with the same sample here studied [21] . Unlike these, we here sought for differences between carriers and noncarriers after accounting for demographic and diagnostic factors.…”
Section: Discussioncontrasting
confidence: 99%
“…Although this increase is more pronounced in Aβ‐positive than in negative individuals (as shown by the β slopes), the fact that there is no interaction between Aβ and age indicates that Aβ does not significantly modify the association between age and the specific CSF biomarker. These results are in line with previous studies that show that glial biomarkers increase with aging and also in other neurological diseases besides AD 27‐36 . Of note, our sample comprises a higher prevalence of A+T– than A+T+ individuals.…”
Section: Discussionsupporting
confidence: 93%
